NTCELL® Clinical Study in Parkinson’s Meets Endpoints

Living Cell Technologies Advancing Regenerative Cell Therapy into Larger Phase IIb Study to Evaluate Its Potential as a Disease-modifying Treatment
Company to Host Conference Call on Thursday 18 June at 8:30 a.m. AEST / 10:30 a.m. NZT

The Phase I/IIa clinical study of NTCELL®, conducted in four patients in New Zealand, met its primary endpoint of safety, showing NTCELL implantation was well tolerated, with no adverse events considered to be related to NTCELL. NTCELL implantation also improved clinical features of Parkinson’s disease in the four patients studied, as measured by validated neurological rating scales and questionnaires, with the improvement sustained at 26 weeks post-implant.

LCT plans to initiate the confirmatory Phase IIb study in the fourth quarter of 2015. The study will be led by Dr. Snow at Auckland City Hospital. The efficacy and safety endpoints will be the same as those evaluated in the Phase I/IIa study.